

PRESS RELEASE April 17, 2007

Invitation to press and analyst meeting and conference call

Presentation of Interim Report for January- March 2007

The biopharma company Biovitrum, invites media and analysts to a press- and analyst meeting in Stockholm and conference call on Monday April 23 in conjunction with the disclosure of the Interim Report for January-March 2007. The report is scheduled for publication at 08:30 (CET) the same day.

The report will be presented by CEO Mats Pettersson and CFO Göran Arvidson.

Press and analyst meeting in Stockholm

Time: Monday, April 23 at 10:30 (CET)
Venue: IVA, Grev Turegatan 16, Stockholm, conference room "Wenström"
Coffee will be served following the presentation.

Please register not later than 16:00 (CET) on Friday April 20, by either sending e-mail to marianne.gripe@biovitrum.com or contacting Marianne Gripe at +46 8 697 34 27.

Conference Call

Time: Monday , April 23 at 14:30 (CET)
Dial-in: +46 8 566 363 29

A recorded version of the conference call will be available for seven days on phone no: +46 8 506 269 49 access code: 163303#

The slide presentation from the conference will be available on [www.biovitrum.com / investor relations/ presentations](http://www.biovitrum.com/investor-relations/presentations).

For more information, please contact:

Biovitrum AB (publ)

Anders Martin-Löf, Director Investor Relations
Phone: +46 8 697 37 07, Mobile: +46 70 624 32 56
anders.martin-lof@biovitrum.com

Anna Karin Källén, Vice President, Corporate Communications
Phone: +46 8 697 20 85, Mobile: +46 73 433 20 85
annakarin.kallen@biovitrum.com

About Biovitrum

Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com/.